Table 2 Summary of pooled ORs with CI in the meta-analysis
From: Will metformin use lead to a decreased risk of thyroid cancer? A systematic review and meta-analyses
Group | No. of studies | Heterogeneity | Significant | OR (95%CI) | Model | ||
|---|---|---|---|---|---|---|---|
I2 (%) | Pheterogeneity | Z | P | ||||
Overall | 5 | 77.7 | 0.001 | 2.56 | 0.011 | 0.68 (0.50–0.91) | Random |
Study design | Â | Â | Â | Â | Â | Â | Â |
 Case–control studies | 2 | 80.8 | 0.023 | 0.29 | 0.774 | 0.89 (0.40–1.99) | Random |
 Cohort studies | 3 | 83.3 | 0.002 | 2.36 | 0.018 | 0.61 (0.41–0.92) | Random |
Geographic locations | Â | Â | Â | Â | Â | Â | Â |
 Western | 3 | 65.9 | 0.053 | 0.41 | 0.685 | 0.89 (0.52–1.54) | Random |
 Eastern | 2 | 90.6 | 0.001 | 2.52 | 0.012 | 0.55 (0.35–0.88) | Random |
Sample size | Â | Â | Â | Â | Â | Â | Â |
 < 10,000 | 2 | 80.8 | 0.023 | 0.29 | 0.774 | 0.89 (0.40–1.99) | Random |
 ≥ 10,000 | 3 | 83.3 | 0.002 | 2.36 | 0.018 | 0.61 (0.41–0.92) | Random |
Quality | Â | Â | Â | Â | Â | Â | Â |
 Moderate | 1 | NA | NA | 0.03 | 0.979 | 0.99 (0.46–2.12) | NA |
 High | 4 | 82.0 | 0.001 | 2.65 | 0.008 | 0.65 (0.47–0.89) | Random |